Dr.Rahiminejad Roozbeh Hospital TUMS

Similar documents
Diagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD

Quick Guide to Common Antidepressants-Adults

Treat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused

PSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer

Presentation is Being Recorded

9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded

Adult Depression - Clinical Practice Guideline

Depression & Anxiety in Adolescents

Depression. University of Illinois at Chicago College of Nursing

The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders What are functional GI disorders?

Common Antidepressant Medications for Adults

Children s Hospital Of Wisconsin

Review of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)

Mental Illness. Doreen L. Rasp, APN, FNP, PMHNP Advanced Behavioral Counseling

Depression in the Medically Ill

Psychiatry in Primary Care: What is the Role of Pharmacist?

Using Drugs to Improve the Behavior of People with Autism: A Skeptical Appraisal. Alan Poling, Ph.D., BCBA-D Western Michigan University

Daniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School

Schedule FDA & literature based indications

Chronic Pain Care Management in Primary Care 12/16/2010. Jürgen Unützer, MD, MPH, MA UW Psychiatry and Behavioral Sciences

Antidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry

Medically Accepted Indications for Pediatric Use of Psychotropic Medications by

A Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer

Psychiatry curbside: Answers to a primary care doctor s top mental health questions

Does cymbalta cause weight gain

Medications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation

FROM MEDICATION TO MINDFULNESS: NEW INSIGHTS INTO THE WORLD OF ANXIETY

Index. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers

Pharmacists in Medication Adherence in Psychiatric Patients

It is the policy of health plans affiliated with Centene Corporation that Seroquel XR is medically necessary when the following criteria are met:

Depression major depressive disorder. Some terms: Major Depressive Disorder: Major Depressive Disorder:

Prepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D.

Medications and Children Disorders

COMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications*

Depression: Identification, Evaluation and Management in Primary Care

Diabetes and Depression. Roshini Pinto-Powell, MD Stephen Noyes, LICSW, LADC William Gunn, PhD Beverly Bean, RN, C

Major Depressive Disorder (MDD) in Children under Age 6

BRIEF ANTIDEPRESSANT OVERVIEW. Casey Gallimore, Pharm.D., M.S.

ERIC J. NESTLER, MD, PhD

ANTI-DEPRESSANT MEDICATIONS

Psychobiology Handout

Management of SSRI Induced Sexual Dysfunction. Serotonin Reuptake Inhibitors*

Guide to Psychiatric Medications for Children and Adolescents

Non-A, non-b=hcv; IFN/RBV; DSM-5/Ham-D, OLT; SSRI, P450

CHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XIV, 2012 INDEX

Psychiatric Illness. In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis

PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES

Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment

Judges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children

Joel V. Oberstar, M.D. 1

KEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.

Professional Practice Minutes September 7 th, 2016

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist

Psychiatric Medication Guide

Dr Yong Mo Juin. Consultant. GP Symposium 23rd April 2016

Depression in Late Life

Introduction to Drug Treatment

Major Depression and Anxiety in Adolescents and Adults

Guidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

Pharmacotherapy of Anxiety Disorders (GAD, Panic, & SAD) Declaration of Interests

Volume 4; Number 5 May 2010

Too Many Meds? How to Prevent Polypharmacy in People with Intellectual/Developmental Disabilities

Anti- Depressants, Mood Stabilizers: What Works Best For Bipolar Disorder? Date: March 30, 2007 Source: NIH/National Institute of.

PSYCHIATRY INTAKE FORM

Psychiatric Treatment of the Concussed Athlete

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

Medication for Anxiety and Depression. PJ Cowen Department of Psychiatry, University of Oxford

Presenter Disclosure. Objectives 6/5/2017. Depression, Anxiety, PTSD: A Focus on Pharmacotherapy

Family Medicine Forum November 10, 2017 Montreal., Quebec. Jon Davine, CCFP, FRCP(C) Associate Professor, McMaster University

The Pharmacist's Role in Major Depressive Disorder: Optimizing Care. Welcome We will begin shortly.

MEDICATION ALGORITHM FOR ANXIETY DISORDERS

CHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XV, 2013 INDEX

Medications Guide: Public Speaking And Social Anxiety

Mental Health and Diabetes: Why Do We Need an Integrative Approach?

Diabetes Specific Features. Dealing with Diabetes and Depression. Diabetes Nepal Depression. Overview. Depression. Risk factors for Depression

Resistance is not futile: working with refractory depression and anxiety

Mood Disorders.

90 dosage units per 90 days OR. Extended-release Formulations Ultram ER 90 dosage units per 90 days OR

Clinical Guideline for the Management of Bipolar Disorder in Adults

This initial discovery led to the creation of two classes of first generation antidepressants:

Treating Chronic Illness in the PCMH Handout - Depression. A. Guidelines. 1. Control of Symptoms:

Major Depressive Disorder (MDD) in Children under Age 6

IMPORTANT NOTICE. Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members

Antidepressant Selection in Primary Care

Depressive Disorders A clinical overview. Dr. Scott Yarosh, Medical Director, Behavioral Health

Realities of Depression in Primary Care Setting

Augmentation and Combination Strategies in Antidepressants treatment of Depression

Focusing on Depression in the Community. Kelly N. Gable, Pharm.D., BCPP Associate Professor SIUE School of Pharmacy

Drugs for Emotional and Mood Disorders Chapter 16

Managing Anxiety Disorder in Primary Care

VA/DoD Clinical Practice Guideline for Management of Post Traumatic Stress. Core Module

Psychiatric Medications. Positive and negative effects in the classroom

Depression: Identification, Evaluation and Management in Primary Care

MANAGEMENT OF VISCERAL PAIN

Clinical Policy: Levomilnacipran (Fetzima) Reference Number: HIM.PA.125 Effective Date: Last Review Date: 11.18

Overview and Update on Current Psychopharmacological Medications, Including New Medications in Clinical Trials

Disclosures. Learning Objectives. Psychopharmacology of Pediatric Anxiety and Depression 5/4/2017

Ruby Williams, M.D. Drugs, Alcohol and Sleep February 24, 2018

10/27/09! Psychopharmacology 101 for the LADC! Disclosures! Lecture outline! Structural divisions of the nervous system!

Transcription:

Dr.Rahiminejad Roozbeh Hospital TUMS

Psychiatric disorders, particularly depression, anxiety and eating disorders, are prevalent in diabetes. Mental illness increases risk of diabetes and diabetic complications. Diabetes and depression are major public health problems associated with significant burden. Both the diseases have a very high prevalence, mortality, and disability.

Epidemiology of depression and diabetes Depression is common in both type 1 and type 2 diabetes and has significant effects on the course and outcome of this medical illness. The prevalence rate of depression is more than threetimes higher in people with type 1 diabetes and nearly twice as high in people with type 2 diabetes compared to those without. Roy T1, Lloyd CE. 2012 Oct (a systematic review)

Epidemiology of depression and diabetes In people with diabetes, the prevalence of clinically relevant depressive symptoms is 31% and that of major depression is 11% (Anderson et al., 2001). Depression is associated with hyperglycemia and an increased risk for diabetic complications. People with depressive disorders have a 65% increased risk of developing diabetes (Campayo et al., 2010).

The prognosis of both diabetes and depression (in terms of complications, treatment resistance and mortality) is worse when the two diseases are comorbid than when they occur separately.

Several factors were correlated with depression in type 2 diabetes, such as low levels of education, physical inactivity, and physical impairments and limitations. In type 1 diabetes, low levels of education and physical impairment and limitation were correlated with depression. Women with diabetes and also women without diabetes experience a higher prevalence of depression than men.

Depression and diabetes complications A prospective association has been documented between prior depressive symptoms and the onset of coronary artery disease in people with diabetes (Orchard et al., 2003). A prospective association has been found between depression and the onset of retinopathy in children with diabetes. In types 1 and 2 diabetes, a large proportion of subjects had one or more comorbid chronic somatic diseases with cardiovascular diseases being the most prevalent condition.

Depressive symptoms are more common in diabetes patients with macro- and micro-vascular problems, such as erectile dysfunction and diabetic foot disease, although the causal direction of the relationship is unclear. From Lloyd CE et al. The epidemiology of depression and diabetes. In: Depression and Diabetes. Katon W, Maj M, Sartorius N (eds). Chichester: Wiley, 2010.

Depression is a phenotype for a range of stress-related disorders which lead to an activation of the hypothalamic-pituitary-adrenal axis, a dysregulation of the autonomic nervous system and a release of proinflammatory cytokines, ultimately resulting in insulin resistance. From Ismail K. Unravelling the pathogenesis of the depression-diabetes link. In: Depression and Diabetes. Katon W, Maj M, Sartorius N (eds). Chichester: Wiley, 2010.

Depression is associated with reduced physical activity, which increases the risk for obesity and consequently for type 2 diabetes.

Concurrent depression is associated with: Decrease in metabolic control Poor adherence to medication, diet regimens, exercising and monitoring of blood glucose Increase in health care expenditures Reduction in quality of life In turn, poor metabolic control may exacerbate depression and diminish response to antidepressant regimens.

Screening for depression and anxiety is important in patients with diabetes Purpose Diabetes-specific Quality of Life Depression/Anxiety Tools Problem Areas in Diabetes (PAID) Scale Diabetes Distress Scale (DDS) WHO-5 Hospital Anxiety and Depression Scale (HADS) Patient Health Questionnaire (PHQ-9) Beck Depression Inventory (BDI)

Treatment Psychotherapy and pharmacotherapy are effective in the presence of diabetes; both cognitive behavior therapy and selective serotonin reuptake inhibitors are weight neutral and have been associated with glycemic improvement in some studies.

Psychotherapy CBT is more effective at improving HbA1c levels at sixmonth follow-up than education alone. Psychosocial interventions should be integrated into diabetes care plans. Consider adjunctive brief psychotherapy for: Emotional eating (cognitive-behavioral therapy) Breaking down problems (problem-solving therapy) Improving treatment adherence (motivational interviewing)

Stress management strategies Coping skills training Family therapy Establishing relationships that are empowering and non-judgemental If a person feels judged, they will become defensive. If a person feels guilt/shame, they will become avoidant.

Medication adherence is one of the fundamental health behaviours of relevance to self-management and chronic disease outcomes. WHO estimates nonadherence to medication at 30% - 70% of medications for chronic conditions.

SSRIs Pharmacotherapy Fluoxetine (Prozac) Sertraline (Zoloft) Fluvoxamine (Luvox) Citalopram (Celexa) Escitalopram (Lexapro) Paroxetine (Paxil, CR) *Commonly used in anxiety disorders; + only FDA approved drug for pediatrics

The increased risk of diabetes was particularly notable for the selective serotonin-reuptake inhibitor (SSRI) paroxetine and the tricyclic antidepressant amitriptyline.

SSRIs Mechanism selective reuptake inhibition of serotonin First-line therapy Fluoxetine only FDA approved agent for children/adolescents Similar or superior efficacy to others Lower side effects, safer, convenient dosing Generally choose cheapest available Recognize differences between agents

SNRIs Venlafaxine (Effexor) Duloxetine (Cymbalta) Also has indications for diabetic peripheral neuropathy and generalized anxiety disorder

SNRI s Mechanism selective serotonin and norepinephrine reuptake inhibition Common side effects: Nausea, dizziness, insomnia, constipation, sweating Venlafaxine can cause hypertension

Catacholamine reuptake inhibitor Bupropion (Wellbutrin) Mechanism Weak inhibitor of norepinephrine and dopamine uptake, no effect on serotonin Lowers the seizure threshold, especially in bulimic patients Has mild stimulating properties May be useful for patients presenting with difficulty concentrating or fatigue Does not cause sexual dysfunction

Consider medication: Comorbid depression and anxiety: SSRI or SNRI Sexual dysfunction: use bupropion or, if already responding to SSRI, add buspirone Significant neuropathy: choose bupropion, venlafaxine or duloxetine due to effectiveness in treating neuropathic pain

Psychoactive Medications May Predispose to Diabetes Patients with schizophrenia are at increased risk of developing metabolic disorders like type 2 diabetes. Especially second-generation antipsychotics (olanzapine, clozapine, risperidone, quetiapine, aripiprazole, ziprasidone) Biochemical and lifestyle factors may also contribute

There are several potential mechanisms behind antipsychotic-induced diabetes, including the weight gain associated with these medications, the effects on pancreatic receptors and/or glucose transporters, or some other cause not yet discovered.

ساله ای با سابقه 5 ساله دیابت گزارشی ازشروع عالیم اساسی از یک ماه قبل می دهد.اولین اقدام مهم آقای 20 افسردگی

درمان در سنین نوجوانی درمان در بارداری و شیردهی درمان در سالمندان

Conclusions The prevalence of depression is 2 fold greater in patients with diabetes. Better detection/screening is essential to improving diabetes self-care Future multidisciplinary management approaches are critical in the identification, treatment and follow up in our diabetes patients.

Mental illness increases risk of diabetes and diabetic complications Mental Illness Diabetes Non-adherence to medication and self-care Functional impairment Risk of complications Healthcare costs Risk of early mortality Depression increases risk of DM by 60%!

سپاس